CSIMarket



Gilead Sciences Inc   (GILD)
Other Ticker:  
 
 

GILD's EPS from Cont. Operations Growth by Quarter and Year

Gilead Sciences Inc 's EPS from Cont. Operations results by quarter and year




GILD EPS from Cont. Operations (in $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 0.30 1.23 2.13
III Quarter September - 2.06 0.29 -0.92
II Quarter June - 1.21 -2.66 1.48
I Quarter March 0.02 1.38 1.23 1.55
FY   0.02 4.95 0.09 4.24



GILD EPS from Cont. Operations first quarter 2022 Y/Y Growth Comment
Gilead Sciences Inc reported drop in EPS from Cont. Operations in the first quarter 2022 by -98.55% to $ 0.02 , from the same quarter in 2021.
The fall in the first quarter 2022 Gilead Sciences Inc 's EPS from Cont. Operations compares unfavorably to the Company's average EPS from Cont. Operations rise of 34.57%.

Looking into first quarter 2022 results within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher EPS from Cont. Operations growth. While Gilead Sciences Inc ' s EPS from Cont. Operations meltdown of -98.55% ranks overall at the positon no. 1317 in the first quarter 2022.




GILD EPS from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -75.61 % -42.25 % -
III Quarter September - 610.34 % - -
II Quarter June - - - 5.71 %
I Quarter March -98.55 % 12.2 % -20.65 % 31.36 %
FY   - 5400 % -97.88 % 0.95 %

Financial Statements
Gilead Sciences Inc 's first quarter 2022 EPS from Cont. Operations $ 0.02 GILD's Income Statement
Gilead Sciences Inc 's first quarter 2021 EPS from Cont. Operations $ 1.38 Quarterly GILD's Income Statement
New: More GILD's historic EPS from Cont. Operations Growth >>


GILD EPS from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -85.44 % 324.14 % -
III Quarter September - 70.25 % - -
II Quarter June - -12.32 % - -4.52 %
I Quarter March -93.33 % 12.2 % -42.25 % -
FY (Year on Year)   - 5400 % -97.88 % 0.95 %




EPS from Cont. Operations first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #12
Healthcare Sector #100
Overall #1317

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
1580.41 % 34.57 % -90.4 %
(Jun 30 2021)   (Dec 31 2020)
EPS from Cont. Operations first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #12
Healthcare Sector #100
Overall #1317
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
1580.41 % 34.57 % -90.4 %
(Jun 30 2021)   (Dec 31 2020)

EPS from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Gilead Sciences Inc 's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
66601.67 % 1081.84 % -99.86 %
(Mar 31 2019)  


GILD's I. Quarter Q/Q EPS from Cont. Operations Comment
In the I. Quarter 2022 Gilead Sciences Inc disclosed fall in EPS from Cont. Operations from the previous quarter by -93.33% to $ 0.02 , from $ 0.30 released in the previous reporting period.

Even cyclical influence which commonly elevate I. Quarter 2022 results, this simply has not been sufficient to salvage GILD's performance, Elisabeth  Hall, Healthcare sector insider situated in Houston wrote and continued that average sequential EPS from Cont. Operations growth is at 1081.84% for Gilead Sciences Inc .

Within Biotechnology & Pharmaceuticals industry 9 other companies have achieved higher EPS from Cont. Operations quarter on quarter growth. While Gilead Sciences Inc 's EPS from Cont. Operations growth quarter on quarter, overall rank is 1236.


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #10
Healthcare Sector #90
Overall #1236
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #10
Healthcare Sector #90
Overall #1236
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
66601.67 % 1081.84 % -99.86 %
(Mar 31 2019)  


GILD's I. Quarter Q/Q EPS from Cont. Operations Comment
In the I. Quarter 2022 Gilead Sciences Inc realized fall in EPS from Cont. Operations from the previous quarter by -93.33% to $ 0.02 , from $ 0.30 declared in the previous quarter.

Even seasonal factors that normally elevate I. Quarter 2022 EPS from Cont. Operations, could not recover the I. Quarter for the Gilead Sciences Inc , Elisabeth  Hall, Healthcare sector insider situated in Houston pointed out, she detected further difficulties ahead for the Biotechnology & Pharmaceuticals's company.

Within Biotechnology & Pharmaceuticals industry 9 other companies have achieved higher EPS from Cont. Operations quarter on quarter growth. While Gilead Sciences Inc 's EPS from Cont. Operations growth quarter on quarter, overall rank is 1236.


Gilead Sciences Inc 's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative EPS from Cont. Operations 12 Months Ending $ 3.59 $ 4.95 $ 5.88 $ 4.11 $ 0.24
Y / Y EPS from Cont. Operations Growth (TTM) 1367.66 % 5121.63 % 495.72 % - -93.75 %
Year on Year EPS from Cont. Operations Growth Overall Ranking # 21 # 8 # 89 # 0 # 1196
Seqeuential EPS from Cont. Operations Change (TTM) -27.45 % -15.82 % 43.01 % 1580.41 % 158.11 %
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # 1317 # 1308 # 253 # 16 # 125




Cumulative EPS from Cont. Operations growth Comment
Assuming the Gilead Sciences Inc 's fiscal year would have ended in Mar 31 2022, Gilead Sciences Inc would have reprted above average annual EPS from Cont. Operations surge of 1367.66% year on year, of $ 4 .
This marks a slow-down of the companys growth trends and from the 5121.63% surge in Dec 31 2021.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While EPS from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 8 to 21.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
1580.41 %
34.57 %
-90.4 %
 

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 12
Healthcare Sector # 3
Overall # 21

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
5121.63 %
144.51 %
-97.76 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 12
Sector # 100
S&P 500 # 1317
Cumulative EPS from Cont. Operations growth Comment
Assuming the Gilead Sciences Inc 's fiscal year would have ended in Mar 31 2022, Gilead Sciences Inc would have reprted above average annual EPS from Cont. Operations surge of 1367.66% year on year, of $ 4 .
This marks a slow-down of the companys growth trends and from the 5121.63% surge in Dec 31 2021.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month EPS from Cont. Operations growth. While EPS from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 8 to 21.

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
1580.41 %
34.57 %
-90.4 %
 


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 12
Healthcare Sector # 3
Overall # 21

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
5121.63 %
144.51 %
-97.76 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 12
Sector # 100
S&P 500 # 1317




Other EPS from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
GILD's EPS from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for GILD's Competitors
EPS from Cont. Operations Growth for Gilead Sciences Inc 's Suppliers
EPS from Cont. Operations Growth for GILD's Customers

You may also want to know
GILD's Annual Growth Rates GILD's Profitability Ratios GILD's Asset Turnover Ratio GILD's Dividend Growth
GILD's Roe GILD's Valuation Ratios GILD's Financial Strength Ratios GILD's Dividend Payout Ratio
GILD's Roa GILD's Inventory Turnover Ratio GILD's Growth Rates GILD's Dividend Comparisons



Companies with similar EPS from Cont. Operations surge for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Mar 31 2022
Msa Safety Inc-3.23%$ -3.226 
Lemaitre Vascular Inc-3.45%$ -3.448 
Idexx Laboratories Inc-3.77%$ -3.766 
Merit Medical Systems Inc-5.00%$ -5.000 
Addus Homecare Corporation-5.26%$ -5.263 
National Research Corporation-5.56%$ -5.556 
Amgen Inc -5.61%$ -5.614 
Petmed Express Inc-11.44%$ -11.436 
Organon and Co -12.18%$ -12.179 
Regeneron Pharmaceuticals Inc -13.80%$ -13.800 
Natus Medical Inc-14.29%$ -14.286 
Intuitive Surgical Inc -15.24%$ -15.235 
Quest Diagnostics Inc-15.63%$ -15.625 
Universal Health Services Inc -16.67%$ -16.667 
Encompass Health Corporation-18.52%$ -18.519 
Biomx Inc -22.86%$ -22.857 
Davita Inc -22.94%$ -22.936 
Biogen Inc -23.70%$ -23.704 
Hologic Inc-24.58%$ -24.583 
Lifevantage Corp-25.00%$ -25.000 
Integrated Biopharma Inc-25.00%$ -25.000 
Molecular Templates Inc -25.49%$ -25.490 
Fulgent Genetics Inc -26.87%$ -26.868 
Integra Lifesciences Holdings Corp-27.78%$ -27.778 
Reynolds Consumer Products Inc -28.57%$ -28.571 
National Healthcare Corp-28.78%$ -28.777 
Incyte Corp-29.17%$ -29.167 
Semler Scientific inc -31.51%$ -31.507 
Align Technology inc -32.68%$ -32.677 
Laboratory Corporation Of America Holdings-33.12%$ -33.122 


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

HCMC's Profile

Stock Price

HCMC's Financials

Business Description

Fundamentals

Charts & Quotes

HCMC's News

Suppliers

HCMC's Competitors

Customers & Markets

Economic Indicators

HCMC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071